

August 13, 2019



# **Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update**

***Conference Call Scheduled for Thursday, August 15<sup>th</sup> at 4:30pm ET***

**SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019** / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2019 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website approximately one day after the teleconference).

The teleconference will include a Company presentation followed by a question & answer period.

Date: Thursday, August 15, 2019.  
Time: 4:30 PM Eastern Time (ET).

To attend this teleconference, live by telephone:  
Dial-in: (844) 602-0380 (North America); (862) 298-0970 (International)  
Verbal Passcode (for the operator): PBI Second Quarter 2019 Financial Call & Business Update

For those unable to participate in the live teleconference, a replay will be available beginning Friday, August 16, 2019. The replay will be accessible via telephone and the Company's website for 30 days.

Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int'l); Replay Passcode: 53312

## **About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology™, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in

the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology™ (“UST™”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link:  
<http://www.pressurebiosciences.com>.

Please visit us on Facebook, LinkedIn, and Twitter.

**CONTACT:**

Richard T. Schumacher, President & CEO  
(T) 508-230-1828  
(F) 508-230-1829

**SOURCE:** Pressure BioSciences, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/555797/Pressure-BioSciences-Inc-to-Discuss-Second-Quarter-2019-Financial-Results-and-Provide-Business-Update>